Shopping Cart 0
Cart Subtotal
USD 0

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Catenin Beta 1 (Beta Catenin or CTNNB1)-Pipeline Review, H2 2018

Summary

Catenin Beta 1 (Beta Catenin or CTNNB1)-Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease, Non Malignant Disorders and Respiratory which include indications Colorectal Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Familial Adenomatous Polyposis, Hemangiomas, Hepatic (Liver) Tumor, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Liver Cirrhosis, Metastatic Adenocarcinoma of The Pancreas, Myelodysplastic Syndrome, Prostate Cancer and Scar.

The latest report Catenin Beta 1-Pipeline Review, H2 2018, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Catenin Beta 1 (Beta Catenin or CTNNB1)-Overview

Catenin Beta 1 (Beta Catenin or CTNNB1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1)-Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

Boston Biomedical Inc

Circle Pharma Inc

Fog Pharmaceuticals Inc

Marina Biotech Inc

Propanc Biopharma Inc

Catenin Beta 1 (Beta Catenin or CTNNB1)-Drug Profiles

BBI-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exisulind-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Hepatoblastoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRP-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WX-024-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Catenin Beta 1 (Beta Catenin or CTNNB1)-Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1)-Product Development Milestones

Featured News & Press Releases

Aug 09, 2018: Propanc Biopharma selected to present at the 25th Annual NewsMakers in the Biotech Industry

Apr 10, 2018: Propanc Biopharma Completes Scientific Advice Meeting with MHRA

Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP

Feb 20, 2018: Propanc Biopharma Receives Allowance of Key Patent Application in the EU

Dec 28, 2017: Propanc Biopharma to Present at the 10th Annual Biotech Showcase 2018

Nov 27, 2017: Propanc Biopharma to Present at the 10th Annual LD Micro Main Event

Oct 19, 2017: Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP

Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies

Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study

Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP

Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017

Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aileron Therapeutics Inc, H2 2018

Pipeline by Boston Biomedical Inc, H2 2018

Pipeline by Circle Pharma Inc, H2 2018

Pipeline by Fog Pharmaceuticals Inc, H2 2018

Pipeline by Marina Biotech Inc, H2 2018

Pipeline by Propanc Biopharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Catenin Beta 1 (Beta Catenin or CTNNB1) Therapeutic Products under Development, Key Players in Catenin Beta 1 (Beta Catenin or CTNNB1) Therapeutics, Catenin Beta 1 (Beta Catenin or CTNNB1) Pipeline Overview, Catenin Beta 1 (Beta Catenin or CTNNB1) Pipeline, Catenin Beta 1 (Beta Catenin or CTNNB1) Pipeline Assessment


Companies

Aileron Therapeutics Inc

Boston Biomedical Inc

Circle Pharma Inc

Fog Pharmaceuticals Inc

Marina Biotech Inc

Propanc Biopharma Inc

Catenin Beta 1 (Beta Catenin or CTNNB1)-Pipeline Review, H2 2018

Summary

Catenin Beta 1 (Beta Catenin or CTNNB1)-Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease, Non Malignant Disorders and Respiratory which include indications Colorectal Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Familial Adenomatous Polyposis, Hemangiomas, Hepatic (Liver) Tumor, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Liver Cirrhosis, Metastatic Adenocarcinoma of The Pancreas, Myelodysplastic Syndrome, Prostate Cancer and Scar.

The latest report Catenin Beta 1-Pipeline Review, H2 2018, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Catenin Beta 1 (Beta Catenin or CTNNB1)-Overview

Catenin Beta 1 (Beta Catenin or CTNNB1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1)-Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

Boston Biomedical Inc

Circle Pharma Inc

Fog Pharmaceuticals Inc

Marina Biotech Inc

Propanc Biopharma Inc

Catenin Beta 1 (Beta Catenin or CTNNB1)-Drug Profiles

BBI-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exisulind-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Hepatoblastoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRP-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WX-024-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Catenin Beta 1 (Beta Catenin or CTNNB1)-Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1)-Product Development Milestones

Featured News & Press Releases

Aug 09, 2018: Propanc Biopharma selected to present at the 25th Annual NewsMakers in the Biotech Industry

Apr 10, 2018: Propanc Biopharma Completes Scientific Advice Meeting with MHRA

Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP

Feb 20, 2018: Propanc Biopharma Receives Allowance of Key Patent Application in the EU

Dec 28, 2017: Propanc Biopharma to Present at the 10th Annual Biotech Showcase 2018

Nov 27, 2017: Propanc Biopharma to Present at the 10th Annual LD Micro Main Event

Oct 19, 2017: Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP

Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies

Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study

Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP

Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017

Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aileron Therapeutics Inc, H2 2018

Pipeline by Boston Biomedical Inc, H2 2018

Pipeline by Circle Pharma Inc, H2 2018

Pipeline by Fog Pharmaceuticals Inc, H2 2018

Pipeline by Marina Biotech Inc, H2 2018

Pipeline by Propanc Biopharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Catenin Beta 1 (Beta Catenin or CTNNB1) Therapeutic Products under Development, Key Players in Catenin Beta 1 (Beta Catenin or CTNNB1) Therapeutics, Catenin Beta 1 (Beta Catenin or CTNNB1) Pipeline Overview, Catenin Beta 1 (Beta Catenin or CTNNB1) Pipeline, Catenin Beta 1 (Beta Catenin or CTNNB1) Pipeline Assessment


Companies

Aileron Therapeutics Inc

Boston Biomedical Inc

Circle Pharma Inc

Fog Pharmaceuticals Inc

Marina Biotech Inc

Propanc Biopharma Inc